drugset / Trial / NCT05496231
A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The main purpose of this study was to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals SA (GSK)'s investigational adjuvanted human papillomavirus (HPV) vaccine formulations.
Timeline
- Start
- 2022-08-22
- Primary completion
- 2024-02-23
- Completion
- 2024-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gardasil 9 | Vaccine | — | Intramuscular |
| Subject | HPV9 | Vaccine | — | Intramuscular |